Salarius Pharmaceuticals Files 8-K
Ticker: DCOY · Form: 8-K · Filed: Jun 17, 2024 · CIK: 1615219
Sentiment: neutral
Topics: sec-filing, 8-k
TL;DR
Salarius Pharma filed an 8-K on 6/17, mostly procedural stuff.
AI Summary
On June 17, 2024, Salarius Pharmaceuticals, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits." No specific financial figures or significant business events were detailed in the provided excerpt.
Why It Matters
This filing indicates that Salarius Pharmaceuticals is providing updates to the SEC, which could relate to ongoing operations or financial reporting, though specific details are not in this excerpt.
Risk Assessment
Risk Level: low — The provided excerpt is a standard SEC filing notification and does not contain information that inherently increases or decreases risk.
Key Players & Entities
- Salarius Pharmaceuticals, Inc. (company) — Registrant
- June 17, 2024 (date) — Date of Report
- Delaware (jurisdiction) — State of Incorporation
- 2450 Holcombe Blvd. Suite X Houston, TX 77021 (address) — Principal executive offices
FAQ
What is the primary purpose of this 8-K filing for Salarius Pharmaceuticals?
The filing is for "Other Events" and "Financial Statements and Exhibits" as of June 17, 2024.
What is the exact date of the report?
The date of the report is June 17, 2024.
In which state is Salarius Pharmaceuticals incorporated?
Salarius Pharmaceuticals, Inc. is incorporated in Delaware.
What is the principal executive office address for Salarius Pharmaceuticals?
The principal executive office is located at 2450 Holcombe Blvd. Suite X Houston, TX 77021.
Does the filing mention any specific financial results or significant business developments?
The provided excerpt of the 8-K filing does not detail specific financial results or significant business developments.
Filing Stats: 466 words · 2 min read · ~2 pages · Grade level 11.2 · Accepted 2024-06-17 08:05:28
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 SLRX The Nasdaq Capital Market Indi
Filing Documents
- flks-20240617.htm (8-K) — 28KB
- a061724slrxmdandersonehase.htm (EX-99.1) — 16KB
- image_0.jpg (GRAPHIC) — 75KB
- 0001615219-24-000049.txt ( ) — 275KB
- flks-20240617.xsd (EX-101.SCH) — 2KB
- flks-20240617_lab.xml (EX-101.LAB) — 22KB
- flks-20240617_pre.xml (EX-101.PRE) — 13KB
- flks-20240617_htm.xml (XML) — 3KB
01 Other Events
Item 8.01 Other Events. On June 17, 2024, Salarius Pharmaceuticals, Inc. (the "Company") issued a press release announcing that investigators in the Department of Leukemia at the University of Texas MD Anderson Cancer Center presented clinical data on seclidemstat in patients with myelodysplastic syndrome and chronic myelomonocytic leukemia at the 2024 European Hematology Association Annual Meeting held in Madrid from June 13 -16, 2024. A copy of the press release is filed herewith as Exhibit 99.1 and is incorporated herein by reference.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release of Salarius Pharmaceuticals, Inc., dated June 17, 2024 104 Cover Page Interactive Data File (embedded within the inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SALARIUS PHARMACEUTICALS, INC. Date: June 17, 2024 By: /s/ Mark J. Rosenblum Mark J. Rosenblum Chief Financial Officer